Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Maintenance electroconvulsive therapy in schizophrenia

J. Krepela, L. Hosak, B. Pachlova, M. Hrdlicka,

. 2019 ; 31 (1) : 62-68. [pub] -

Jazyk angličtina Země Chorvatsko

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034658

Grantová podpora
NV16-27243A MZ0 CEP - Centrální evidence projektů

BACKGROUND: The aim of our retrospective naturalistic observational study was to describe the use of maintenance electroconvulsive therapy (M-ECT) in chronic pharmacoresistant schizophrenia. SUBJECTS AND METHODS: We delineated 19 cases of chronic pharmacoresistant schizophrenia (females N=12) recently treated with maintenance electroconvulsive therapy at the Havlickuv Brod Psychiatric Hospital in the Czech Republic. Demographic, clinical and treatment variables were recorded. RESULTS: M-ECT, when applied weekly to monthly mostly over a period of several years, was of no benefit in the treatment of chronic hallucinations and/or delusions. However, it did prove beneficial (p<0.001) in removing chronic serious symptoms like suicidal or violent behavior, automutilation, refusal of food or liquids, stupor or catatonia. Even though almost all of our patients remained hospitalized, we were nonetheless able to transfer them to an unlocked psychiatric ward and let them out for walks or occupational therapy with almost no need for using restraint. No serious adverse side effects of M-ECT were found. CONCLUSIONS: Our study is limited by using only one simple standardized measurement (Clinical Global Impression - Severity) that was retrospective. Another limitation of our retrospective study was that the subjects had not been regularly tested for their cognitive functions. According to our results, M-ECT mitigates the impact of the disease and improves social functioning of the patients. M-ECT does not treat chronic schizophrenia but does make the lives of patients more tolerable. We suggest further research into M-ECT and its clinical application in chronic pharmacoresistant schizophrenia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034658
003      
CZ-PrNML
005      
20191017090344.0
007      
ta
008      
191007s2019 ci f 000 0|eng||
009      
AR
024    7_
$a 10.24869/psyd.2019.62 $2 doi
035    __
$a (PubMed)30948691
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ci
100    1_
$a Krepela, Josef $u Psychiatric Hospital, Havlickuv Brod, Czech Republic.
245    10
$a Maintenance electroconvulsive therapy in schizophrenia / $c J. Krepela, L. Hosak, B. Pachlova, M. Hrdlicka,
520    9_
$a BACKGROUND: The aim of our retrospective naturalistic observational study was to describe the use of maintenance electroconvulsive therapy (M-ECT) in chronic pharmacoresistant schizophrenia. SUBJECTS AND METHODS: We delineated 19 cases of chronic pharmacoresistant schizophrenia (females N=12) recently treated with maintenance electroconvulsive therapy at the Havlickuv Brod Psychiatric Hospital in the Czech Republic. Demographic, clinical and treatment variables were recorded. RESULTS: M-ECT, when applied weekly to monthly mostly over a period of several years, was of no benefit in the treatment of chronic hallucinations and/or delusions. However, it did prove beneficial (p<0.001) in removing chronic serious symptoms like suicidal or violent behavior, automutilation, refusal of food or liquids, stupor or catatonia. Even though almost all of our patients remained hospitalized, we were nonetheless able to transfer them to an unlocked psychiatric ward and let them out for walks or occupational therapy with almost no need for using restraint. No serious adverse side effects of M-ECT were found. CONCLUSIONS: Our study is limited by using only one simple standardized measurement (Clinical Global Impression - Severity) that was retrospective. Another limitation of our retrospective study was that the subjects had not been regularly tested for their cognitive functions. According to our results, M-ECT mitigates the impact of the disease and improves social functioning of the patients. M-ECT does not treat chronic schizophrenia but does make the lives of patients more tolerable. We suggest further research into M-ECT and its clinical application in chronic pharmacoresistant schizophrenia.
650    _2
$a katatonie $7 D002389
650    12
$a elektrokonvulzívní terapie $7 D004565
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    12
$a schizofrenie $x terapie $7 D012559
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Hosak, Ladislav
700    1_
$a Pachlova, Barbora
700    1_
$a Hrdlicka, Michal
773    0_
$w MED00006897 $t Psychiatria Danubina $x 0353-5053 $g Roč. 31, č. 1 (2019), s. 62-68
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30948691 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191017090812 $b ABA008
999    __
$a ok $b bmc $g 1451318 $s 1073208
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 31 $c 1 $d 62-68 $e - $i 0353-5053 $m Psychiatria Danubina $n Psychiatr Danub $x MED00006897
GRA    __
$a NV16-27243A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...